株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腸炎:パイプライン製品の分析

Enterocolitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 293885
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
腸炎:パイプライン製品の分析 Enterocolitis - Pipeline Review, H2 2016
出版日: 2016年10月29日 ページ情報: 英文 43 Pages
概要

腸炎とは大腸および小腸の炎症のことを指します。主な症状には、発熱や腹部膨満、吐き気、下痢、直腸出血、倦怠感などがあります。腸炎の要因として、腸内組織の炎症や、胃内容排出の遅滞、腹壁部の紅斑症、無呼吸発作、化膿症、心血管虚脱などが挙げられます。主な治療法には抗生物質などが含まれています。

当レポートでは、世界各国での腸炎(全腸炎、小腸結腸炎)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

腸炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

腸炎:企業で開発中の治療薬

腸炎:大学/機関で研究中の治療薬

腸炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

腸炎:企業で開発中の製品

腸炎:大学/機関で研究中の製品

腸炎の治療薬開発に従事している企業

  • Angothera GmbH
  • AvidBiotics Corp.
  • Infant Bacterial Therapeutics AB
  • Sigma-Tau Pharmaceuticals, Inc

腸炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

腸炎:最近のパイプライン動向

腸炎:休止中のプロジェクト

腸炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8602IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Enterocolitis.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Enterocolitis Overview
  • Therapeutics Development
    • Pipeline Products for Enterocolitis - Overview
    • Pipeline Products for Enterocolitis - Comparative Analysis
  • Enterocolitis - Therapeutics under Development by Companies
  • Enterocolitis - Therapeutics under Investigation by Universities/Institutes
  • Enterocolitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Enterocolitis - Products under Development by Companies
  • Enterocolitis - Products under Investigation by Universities/Institutes
  • Enterocolitis - Companies Involved in Therapeutics Development
    • Angothera GmbH
    • AvidBiotics Corp.
    • Infant Bacterial Therapeutics AB
    • Sigma-Tau Pharmaceuticals, Inc
  • Enterocolitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies for Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AvR2-V10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBP-9414 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRG-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Necrotizing Enterocolitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Enterocolitis - Dormant Projects
  • Enterocolitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
      • Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate
      • Jan 08, 2016: BioGaia's subsidiary IBT has US IND open and Swedish CTA approved for clinical study
      • Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants
      • Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics
      • Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia
      • Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Enterocolitis, H2 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Enterocolitis - Pipeline by Angothera GmbH, H2 2016
  • Enterocolitis - Pipeline by AvidBiotics Corp., H2 2016
  • Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2016
  • Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Enterocolitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Enterocolitis, H2 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top